药物治疗对注意缺陷多动障碍患儿体格生长影响的研究进展

doi:10.11852/zgetbjzz2021-0395

中国儿童保健杂志 ›› 2022, Vol. 30 ›› Issue (8): 874-878.DOI: 10.11852/zgetbjzz2021-0395

药物治疗对注意缺陷多动障碍患儿体格生长影响的研究进展

邓岚柳, 陈立

重庆医科大学附属儿童医院儿童青少年生长发育与心理健康中心/国家儿童健康与疾病临床医学研究中心/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国家国际科技合作基地/认知发育与学习记忆障碍转化医学重庆市重点实验室/儿童营养与健康重庆市重点实验室,重庆 400014

收稿日期:2021-03-22 修回日期:2021-05-13 发布日期:2022-08-17 出版日期:2022-08-10
通讯作者: 陈立,E-mail: chenli@cqmu.edu.cn
作者简介:邓岚柳(1995- ),女,四川人,住院医师,在读硕士研究生,主要研究方向为儿童发育障碍性疾病。
基金资助:
重庆市科卫联合医学科研项目重点项目(2018ZDXM012)。

Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder

DENG Lan-liu, CHEN Li

Growth, Development and Mental Health Center for Children and Adolescents, Children's Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders;Ministry of Education Key Laboratory of Child Development and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Translational; Chongqing Key Laboratory of Child Nutrition and Health, Chongqing 400014, China

Received:2021-03-22 Revised:2021-05-13 Online:2022-08-10 Published:2022-08-17
Contact: CHEN Li,E-mail: chenli@cqmu.edu.cn

摘要/Abstract

摘要： 注意缺陷多动障碍(ADHD)是儿童时期最常见的神经发育障碍性疾病,对儿童的学业水平、人际交往、社会功能以及整个家庭、社会都有不可忽视的影响。ADHD的发病率在过去几十年里一直呈上升趋势。兴奋剂哌甲酯(MPH)与选择性去甲肾上腺素再摄取抑制剂托莫西汀(ATX)均为治疗ADHD公认的一线药物。药物对ADHD儿童体格生长可能带来的消极影响令家长担忧。本文就药物治疗对ADHD患儿体格生长的影响、相关机制及管理进行综述,以期提高患儿临床药物治疗的依从性。

关键词: 注意缺陷多动障碍, 药物治疗, 体格生长, 管理

Abstract: Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder in childhood, which has a significant impact on children's academic performance, interpersonal communication, social functioning, as well as the whole family and society.The incidence of ADHD has been on the rise over the past few decades.Stimulants such as methylphenidate (MPH) and selective norepinephrine reuptake inhibitors such as atomoxetine (ATX), are both commonly used drugs in ADHD treatment.Parents are concerned about the possible negative effects of medication on the physical growth of ADHD children.This article reviews the effects, mechanisms and management of drug therapy on the physical growth of ADHD children, in order to improve the compliance of clinical drug therapy.

Key words: attention-deficit/hyperactivity disorder, drug therapy, physical growth, management

中图分类号:

R749.94

邓岚柳, 陈立. 药物治疗对注意缺陷多动障碍患儿体格生长影响的研究进展[J]. 中国儿童保健杂志, 2022, 30(8): 874-878.

DENG Lan-liu, CHEN Li. Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder[J]. Chinese Journal of Child Health Care, 2022, 30(8): 874-878.

参考文献

[1] Cortese S.Pharmacologic treatment of attention deficit-hyperactivity disorder[J].N Engl J Med, 2020, 383(11):1050-1056.
[2] Wang T, Liu K, Li Z, et al.Prevalence of attention deficit/hyperactivity disorder among children and adolescents in China:A systematic review and meta-analysis[J].BMC psychiatry, 2017, 17(1):32.
[3] Wolraich ML, Chan E, Froehlich T, et al.ADHD diagnosis and treatment guidelines:A historical perspective[J].Pediatrics, 2019, 144(4):e20191682.
[4] Faraone SV, Asherson P, Banaschewski T, et al.Attention-deficit/hyperactivity disorder[J].Nat Rev Dis Primers, 2015, 1:15020.
[5] 中华医学会儿科学分会发育行为学组.注意缺陷多动障碍早期识别、规范诊断和治疗的儿科专家共识[J].中华儿科杂志, 2020, 58(3):188-193.
[6] Beau-Lejdstrom R, Douglas I, Evans SJ, et al.Latest trends in ADHD drug prescribing patterns in children in the UK:Prevalence, incidence and persistence[J].BMJ Open, 2016, 6(6):e010508.
[7] Bachmann CJ,Wijlaars LP, Kalverdijk LJ, et al.Trends in ADHD medication use in children and adolescents in five western countries, 2005—2012[J].Eur Neuropsychopharmacol, 2017, 27(5):484-493.
[8] Man KKC, Ip P, Hsia Y, et al.ADHD drug prescribing trend is increasing among children and adolescents in hong kong[J].J Atten Disord, 2017, 21(14):1161-1168.
[9] Raman SR, Man KKC, Bahmanyar S, et al.Trends in attention-deficit hyperactivity disorder medication use:A retrospective observational study using population-based databases[J].Lancet Psychiatry, 2018, 5(10):824-835.
[10] Klein R, Mannuzza S.Hyperactive boys almost grown up: Ⅲ.Methylphenidate effects on ultimate height[J].Arch Gen Psychiatry, 1988, 45(12):1131-1134.
[11] Safer D, Allen R, Barr E.Growth rebound after termination of stimulant drugs[J].J Pediatr, 1975, 86(1):113-116.
[12] Faraone SV, Biederman J, Morley CP, et al.Effect of stimulants on height and weight:A review of the literature[J].J Am Acad Child Adolesc Psychiatry, 2008, 47(9):994-1009.
[13] Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, et al.Weight, height, and body mass index in patients with attention-deficit/hyperactivity disorder treated with methylphenidate[J].J Child Adolesc Psychopharmacol, 2017, 27(8):723-730.
[14] Durá-Travé T, Yoldi-Petri ME, Gallinas-Victoriano F, et al.Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment[J].J Child Neurol, 2012, 27(5):604-609.
[15] Kim HW, Kim SO, Shon S, et al.Effect of methylphenidate on height and weight in Korean children and adolescents with attention-deficit/hyperactivity disorder:A retrospective chart review[J].J Child Adolesc Psychopharmacol, 2014, 24(8):448-453.
[16] Koonrungsesomboon K, Koonrungsesomboon N.The effects of methylphenidate treatment on child growth in thai children and adolescents with attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol, 2020, 30(3): 189-197.
[17] Faraone SV, Giefer EE.Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth[J].J Am Acad Child Adolesc Psychiatry, 2007, 46(9):1138-1147.
[18] Zachor DA, Roberts AW, Hodgens JB, et al.Effects of long-term psychostimulant medication on growth of children with ADHD[J].Res Dev Disabil, 2006, 27(2):162-174.
[19] 陈立.影响注意缺陷多动障碍的营养因素及管理[J].教育生物学杂志, 2020,8(2):87-93.
[20] Biederman J, Spencer TJ, Monuteaux MC, et al.A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: Sex and treatment effects[J].J Pediatr, 2010, 157(4):635-640.
[21] Zhang H, Du M, Zhuang S.Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD[J].Neuropediatrics, 2010, 41(2): 55-59.
[22] Lentferink YE, van de Garde EMW, Knibbe CAJ, et al.Psychostimulants:Influence on body mass index and height in a pediatric population with attention-deficit/hyperactivity disorder?[J].J Child Adolesc Psychopharmacol, 2018, 28(8):530-536.
[23] Erhart M, Herpertz-Dahlmann B, Wille N, et al.Examining the relationship between attention-deficit/hyperactivity disorder and overweight in children and adolescents[J].Eur Child Adolesc Psychiatry, 2012, 21(1):39-49.
[24] Racicka E, Hanc T, Giertuga K, et al.Prevalence of overweight and obesity in children and adolescents with ADHD:The significance of comorbidities and pharmacotherapy[J].J Atten Disord, 2018, 22(12):1095-1108.
[25] Lingineni RK, Biswas S, Ahmad N, et al.Factors associated with attention deficit/hyperactivity disorder among US children:Results from a national survey[J].BMC Pediatr.2012, 12:50.
[26] Poulton AS, Bui Q, Melzer E, et al.Stimulant medication effects on growth and bone age in children with attention-deficit/hyperactivity disorder:A prospective cohort study[J].Int Clin Psychopharmacol, 2016, 31(2):93-99.
[27] Hanc' T, Cies'lik J, Wolańczyk T, et al.Assessment of growth in pharmacological treatment-naÏve Polish boys with attention-deficit/hyperactivity disorder[J].J Child Adolesc Psychopharmacol, 2012, 22(4):300-306.
[28] Harstad EB, Weaver AL, Katusic SK, et al.ADHD, stimulant treatment, and growth:A longitudinal study[J].Pediatrics, 2014, 134(4):e935-e944.
[29] Greenhill LL, Swanson JM, Hechtman L, et al.Trajectories of growth associated with long-term stimulant medication in the multimodal treatment study of attention-deficit/hyperactivity disorder[J].J Am Acad Child Adolesc Psychiatry, 2020, 59(8):978-989.
[30] Spencer TJ, Kratochvil CJ, Sangal RB, et al.Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment[J].J Child Adolesc Psychopharmacol, 2007, 17(5):689-700.
[31] Kratochvil CJ, Wilens TE, Greenhill LL, et al.Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder[J].J Am Acad Child Adolesc Psychiatry, 2006, 45(8):919-927.
[32] Kweon K, Yoon JS, Park KJ, et al.Effects of atomoxetine on height and weight in korean children and adolescents with attention-deficit/hyperactivity disorder:A retrospective chart review[J].Psychiatry Investig, 2018, 15(6):649-654.
[33] Gurbuz F, Gurbuz BB, Celik GG, et al.Effects of methylphenidate on appetite and growth in children diagnosed with attention deficit and hyperactivity disorder[J].J Pediatr Endocrinol Metab, 2016, 29(1):85-92.
[34] Bou Khalil R, Fares N, Saliba Y, et al.The effect of methylphenidate on appetite and weight[J].Encephale, 2017, 43(6):577-581.
[35] Lee SI, Hong SD, Kim SY, et al.Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder[J].Prog Neuropsychopharmacol Biol psychiatry, 2007, 31(1):210-216.
[36] Graham J, Banaschewski T, Buitelaar J, et al.European guidelines on managing adverse effects of medication for ADHD[J].Eur Child Adolesc Psychiatry, 2011, 20(1):17-37.
[37] Faraone SV.The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities[J].Neurosci Biobehav Rev, 2018, 87:255-270.
[38] Uddin SMZ, Robison LS, Fricke D, et al.Methylphenidate regulation of osteoclasts in a dose- and sex-dependent manner adversely affects skeletal mechanical integrity[J].Sci Rep, 2018, 8(1):1515.
[39] Thanos PK, Robison LS, Steier J, et al.A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior[J].Pharmacol Biochem Behav, 2015, 131(undefined):143-153.
[40] Wang J, Adab P, Liu W, et al.Prevalence of adiposity and its association with sleep duration, quality, and timing among 9-12-year-old children in Guangzhou, China[J].J Epidemiol, 2017, 27(11):531-537.
[41] Michelson D, Read HA, Ruff DD, et al.CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD[J].J Am Acad Child Adolesc Psychiatry, 2007, 46(2):242-251.
[42] Martins S, Tramontina S, Polanczyk G, et al.Weekend holidays during methylphenidate use in ADHD children:A randomized clinical trial[J].J Child Adolesc Psychopharmacol, 2004, 14(2):195-206.
[43] Waxmonsky JG, Baweja R.Editorial: does an attention-deficit/hyperactivity disorder pill a day keep failing grades away?[J].J Am Acad Child Adolesc Psychiatry, 2019, 58(4):395-397.
[44] Cortese S, Holtmann M, Banaschewski T, et al.Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents[J].J Child Psychol Psychiatry, 2013, 54(3):227-246.

药物治疗对注意缺陷多动障碍患儿体格生长影响的研究进展

Research progress on the effect of drug therapy on the physical growth of children and adolescents with attention-deficit/hyperactivity disorder

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李荣, 李年, 吴丹丹, 黄荣, 陈银花. 盐酸哌甲酯缓释片对注意缺陷多动障碍儿童生长的影响[J]. 中国儿童保健杂志, 2023, 31(7): 731-735.
[2]	李玮玮, 张丹丹, 刘晓鸣, 陈娇, 夏露. 探讨基于互联网技术的长程管理模式在难治性癫痫患儿中的应用研究[J]. 中国儿童保健杂志, 2023, 31(7): 781-784.
[3]	郑亭玉, 张春宇, 杨飞, 郑芳, 张梦霞, 夏露萍, 徐孙超. 营养支持小组管理模式对早产儿生长发育及免疫功能的影响[J]. 中国儿童保健杂志, 2023, 31(5): 555-558.
[4]	张婕, 安英萍, 杨毅, 张艳楠, 田琳. 从全生命周期视角识别和治疗注意缺陷多动障碍女童和女性的专家共识(2020年版)解读[J]. 中国儿童保健杂志, 2023, 31(5): 570-575.
[5]	易文霞, 陈立. 注意缺陷多动障碍儿童父母养育压力研究进展[J]. 中国儿童保健杂志, 2023, 31(4): 408-411.
[6]	刘芮卓, 陈立. 儿童注意缺陷多动障碍与肥胖的相关性研究[J]. 中国儿童保健杂志, 2023, 31(4): 412-415.
[7]	买国华. 学龄期支气管哮喘患儿自我管理行为调查及影响因素[J]. 中国儿童保健杂志, 2023, 31(4): 446-450.
[8]	王晶, 项思嘉, 鲁莹, 杨蕾, 胡小沙, 钱君, 池霞, 张敏. 早产儿3周岁体格生长及体成分分析[J]. 中国儿童保健杂志, 2023, 31(4): 457-460.
[9]	朱笑彤, 任园春, 刘靖, 李雪, 王芳, 尹婷妮, 谢永涛, 宋懿芪, 范碧瑶, 吉宁. 注意缺陷多动障碍小学生精细动作发展特点研究[J]. 中国儿童保健杂志, 2023, 31(3): 322-326.
[10]	周梅君, 魏蓉美, 袁晓玲, 赵婷, 赵硕. 小组训练对学龄前注意缺陷多动障碍儿童注意品质的干预效果[J]. 中国儿童保健杂志, 2023, 31(3): 336-340.
[11]	黄琦, 黄欣欣, 钱沁芳, 王章琼, 李国凯. 注意缺陷多动障碍共患发育性协调障碍的学龄前儿童智力结构特征[J]. 中国儿童保健杂志, 2023, 31(2): 136-140.
[12]	梅练妮, 胡纯纯, 徐琼. 脆性X综合征药物治疗进展[J]. 中国儿童保健杂志, 2023, 31(2): 180-184.
[13]	柴润玉, 王康程, 林华伟, 张俊英, 邢婕, 张华, 曹爱华. 注意缺陷多动障碍儿童及其父母攻击行为相互作用的网络分析[J]. 中国儿童保健杂志, 2022, 30(8): 845-850.
[14]	熊华春, 周志恒, 周洋萍, 王军, 朱登纳, 陈精慧. 下肢康复机器人训练联合家庭姿势管理对脑瘫患儿运动功能的疗效研究[J]. 中国儿童保健杂志, 2022, 30(7): 711-714.
[15]	房海波, 王荣, 褚琳娜, 冯艳芳, 白容荣, 郭丰桐. 血清维生素D水平与伴中央颞区棘波的儿童良性癫痫共患注意缺陷多动障碍患儿认知功能的相关性分析[J]. 中国儿童保健杂志, 2022, 30(7): 775-778.